Details of the Drug

General Information of Drug (ID: DMG629M)

Drug Name
Rivastigmine
Synonyms Rivastigmine (transdermal patch)
Indication
Disease Entry ICD 11 Status REF
Alzheimer disease 8A20 Approved [1]
Affected Organisms
Humans and other mammals
ATC Code
N06DA03: Rivastigmine
N06DA: Anticholinesterases
N06D: ANTI-DEMENTIA DRUGS
N06: PSYCHOANALEPTICS
N: NERVOUS SYSTEM
N06DA03: Rivastigmine
N06DA: Anticholinesterases
N06D: ANTI-DEMENTIA DRUGS
N06: PSYCHOANALEPTICS
N: NERVOUS SYSTEM
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 250.34
Logarithm of the Partition Coefficient (xlogp) 2.3
Rotatable Bond Count (rotbonds) 5
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 3
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [2]
Bioavailability
72% of drug becomes completely available to its intended biological destination(s) [3]
Clearance
The renal clearance of drug is 2.1-2.8 L/h []
Elimination
0.1% of drug is excreted from urine in the unchanged form [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 1.5 hours [4]
Metabolism
The drug is metabolized via the cholinesterase-mediated hydrolysis []
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.7989 micromolar/kg/day [5]
Unbound Fraction
The unbound fraction of drug in plasma is 0.6% [4]
Vd
The volume of distribution (Vd) of drug is 1.8-2.7 L/kg []
Chemical Identifiers
Formula
C14H22N2O2
IUPAC Name
[3-[(1S)-1-(dimethylamino)ethyl]phenyl] N-ethyl-N-methylcarbamate
Canonical SMILES
CCN(C)C(=O)OC1=CC=CC(=C1)[C@H](C)N(C)C
InChI
InChI=1S/C14H22N2O2/c1-6-16(5)14(17)18-13-9-7-8-12(10-13)11(2)15(3)4/h7-11H,6H2,1-5H3/t11-/m0/s1
InChIKey
XSVMFMHYUFZWBK-NSHDSACASA-N
Cross-matching ID
PubChem CID
77991
ChEBI ID
CHEBI:8874
CAS Number
123441-03-2
UNII
PKI06M3IW0
DrugBank ID
DB00989
TTD ID
D0WY5Q
ACDINA ID
D00602

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Acetylcholinesterase (AChE) TT1RS9F ACES_HUMAN Modulator [6]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Acetylcholinesterase (ACHE) OT2H8HG6 ACES_HUMAN Gene/Protein Processing [7]
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Gene/Protein Processing [8]
Cholinesterase (BCHE) OTOH3WQ9 CHLE_HUMAN Gene/Protein Processing [9]
Cocaine esterase (CES2) OTC647SQ EST2_HUMAN Gene/Protein Processing [10]
Heat shock factor protein 1 (HSF1) OTYNJ4KP HSF1_HUMAN Gene/Protein Processing [11]
Liver carboxylesterase 1 (CES1) OT9L0LR8 EST1_HUMAN Gene/Protein Processing [10]
Neuronal acetylcholine receptor subunit alpha-4 (CHRNA4) OT1H0ZXC ACHA4_HUMAN Protein Interaction/Cellular Processes [12]
Neuronal acetylcholine receptor subunit beta-2 (CHRNB2) OTNAT2M5 ACHB2_HUMAN Protein Interaction/Cellular Processes [12]
Prostaglandin G/H synthase 2 (PTGS2) OT75U9M4 PGH2_HUMAN Gene/Protein Processing [13]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Alzheimer disease
ICD Disease Classification 8A20
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Acetylcholinesterase (AChE) DTT ACHE 6.39E-02 -1.07 -1.15
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Rivastigmine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Bethanechol DMCLHO0 Moderate Additive cholinergic effects by the combination of Rivastigmine and Bethanechol. Abnormal micturition [MF50] [14]
Midostaurin DMI6E0R Moderate Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Midostaurin. Acute myeloid leukaemia [2A60] [15]
Idarubicin DMM0XGL Moderate Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Idarubicin. Acute myeloid leukaemia [2A60] [15]
Gilteritinib DMTI0ZO Moderate Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Gilteritinib. Acute myeloid leukaemia [2A60] [15]
Oliceridine DM6MDCF Moderate Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Oliceridine. Acute pain [MG31] [15]
Mepyramine DMB4SFH Moderate Antagonize the effect of Rivastigmine when combined with Mepyramine. Allergic/hypersensitivity disorder [4A80-4A8Z] [16]
Phenyltoloxamine DMKAEQW Moderate Antagonize the effect of Rivastigmine when combined with Phenyltoloxamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [16]
Bedaquiline DM3906J Moderate Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [15]
Cilostazol DMZMSCT Moderate Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Cilostazol. Arterial occlusive disease [BD40] [15]
Posaconazole DMUL5EW Moderate Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Posaconazole. Aspergillosis [1F20] [15]
Salbutamol DMN9CWF Moderate Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Salbutamol. Asthma [CA23] [17]
Lisdexamfetamine DM6W8V5 Moderate Increased risk of prolong QT interval by the combination of Rivastigmine and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [18]
Desipramine DMT2FDC Moderate Antagonize the effect of Rivastigmine when combined with Desipramine. Attention deficit hyperactivity disorder [6A05] [19]
Ofloxacin DM0VQN3 Moderate Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Ofloxacin. Bacterial infection [1A00-1C4Z] [15]
Clarithromycin DM4M1SG Moderate Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Clarithromycin. Bacterial infection [1A00-1C4Z] [15]
Sparfloxacin DMB4HCT Moderate Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Sparfloxacin. Bacterial infection [1A00-1C4Z] [15]
Gemifloxacin DMHT34O Moderate Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Gemifloxacin. Bacterial infection [1A00-1C4Z] [15]
Norfloxacin DMIZ6W2 Moderate Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Norfloxacin. Bacterial infection [1A00-1C4Z] [15]
Levofloxacin DMS60RB Moderate Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Levofloxacin. Bacterial infection [1A00-1C4Z] [15]
Retigabine DMGNYIH Moderate Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Retigabine. Behcet disease [4A62] [15]
Eribulin DM1DX4Q Moderate Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Eribulin. Breast cancer [2C60-2C6Y] [15]
Lapatinib DM3BH1Y Moderate Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Lapatinib. Breast cancer [2C60-2C6Y] [15]
Bosutinib DMTI8YE Moderate Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Bosutinib. Breast cancer [2C60-2C6Y] [15]
PF-04449913 DMSB068 Moderate Increased risk of ventricular arrhythmias by the combination of Rivastigmine and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [15]
Olodaterol DM62B78 Moderate Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Olodaterol. Chronic obstructive pulmonary disease [CA22] [15]
Halothane DM80OZ5 Moderate Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Halothane. Corneal disease [9A76-9A78] [15]
Sevoflurane DMC9O43 Moderate Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Sevoflurane. Corneal disease [9A76-9A78] [15]
Probucol DMVZQ2M Moderate Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Probucol. Coronary atherosclerosis [BA80] [15]
Pasireotide DMHM7JS Moderate Increased risk of atrioventricular block by the combination of Rivastigmine and Pasireotide. Cushing syndrome [5A70] [15]
Osilodrostat DMIJC9X Moderate Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Osilodrostat. Cushing syndrome [5A70] [15]
Sertraline DM0FB1J Moderate Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Sertraline. Depression [6A70-6A7Z] [15]
Escitalopram DMFK9HG Moderate Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Escitalopram. Depression [6A70-6A7Z] [15]
OPC-34712 DMHG57U Moderate Antagonize the effect of Rivastigmine when combined with OPC-34712. Depression [6A70-6A7Z] [19]
Clomipramine DMINRKW Moderate Antagonize the effect of Rivastigmine when combined with Clomipramine. Depression [6A70-6A7Z] [19]
Doxepin DMPI98T Moderate Antagonize the effect of Rivastigmine when combined with Doxepin. Depression [6A70-6A7Z] [19]
Mepenzolate DM8YU2F Moderate Antagonize the effect of Rivastigmine when combined with Mepenzolate. Digestive system disease [DE2Z] [19]
Oxybutynine DMJPBAX Moderate Antagonize the effect of Rivastigmine when combined with Oxybutynine. Discovery agent [N.A.] [19]
Tetrabenazine DMYWQ0O Moderate Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [15]
Deutetrabenazine DMUPFLI Moderate Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Deutetrabenazine. Dystonic disorder [8A02] [15]
Ingrezza DMVPLNC Moderate Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Ingrezza. Dystonic disorder [8A02] [15]
Diphenhydramine DMKQTBA Moderate Antagonize the effect of Rivastigmine when combined with Diphenhydramine. Episodic vestibular syndrome [AB31] [19]
Solifenacin DMG592Q Moderate Antagonize the effect of Rivastigmine when combined with Solifenacin. Functional bladder disorder [GC50] [19]
Tolterodine DMSHPW8 Moderate Antagonize the effect of Rivastigmine when combined with Tolterodine. Functional bladder disorder [GC50] [19]
Ketoconazole DMPZI3Q Moderate Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Ketoconazole. Fungal infection [1F29-1F2F] [15]
Sunitinib DMCBJSR Moderate Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Sunitinib. Gastrointestinal stromal tumour [2B5B] [15]
Rilpivirine DMJ0QOW Moderate Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [15]
Belladonna DM2RBWK Moderate Antagonize the effect of Rivastigmine when combined with Belladonna. Infectious gastroenteritis/colitis [1A40] [19]
ITI-007 DMUQ1DO Moderate Antagonize the effect of Rivastigmine when combined with ITI-007. Insomnia [7A00-7A0Z] [19]
Polyethylene glycol DM4I1JP Moderate Increased risk of lowers seizure threshold by the combination of Rivastigmine and Polyethylene glycol. Irritable bowel syndrome [DD91] [20]
Ceritinib DMB920Z Moderate Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Ceritinib. Lung cancer [2C25] [15]
Osimertinib DMRJLAT Moderate Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Osimertinib. Lung cancer [2C25] [15]
Selpercatinib DMZR15V Moderate Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Selpercatinib. Lung cancer [2C25] [15]
Lumefantrine DM29GAD Moderate Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Lumefantrine. Malaria [1F40-1F45] [17]
Halofantrine DMOMK1V Moderate Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Halofantrine. Malaria [1F40-1F45] [15]
Hydroxychloroquine DMSIVND Moderate Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Hydroxychloroquine. Malaria [1F40-1F45] [15]
Primaquine DMWQ16I Moderate Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Primaquine. Malaria [1F40-1F45] [15]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [15]
Arsenic trioxide DM61TA4 Moderate Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Arsenic trioxide. Mature B-cell lymphoma [2A85] [15]
Vemurafenib DM62UG5 Moderate Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Vemurafenib. Melanoma [2C30] [15]
LGX818 DMNQXV8 Moderate Increased risk of prolong QT interval by the combination of Rivastigmine and LGX818. Melanoma [2C30] [21]
Panobinostat DM58WKG Moderate Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Panobinostat. Multiple myeloma [2A83] [15]
Thalidomide DM70BU5 Moderate Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Thalidomide. Multiple myeloma [2A83] [17]
Siponimod DM2R86O Major Increased risk of bradycardia by the combination of Rivastigmine and Siponimod. Multiple sclerosis [8A40] [17]
Fingolimod DM5JVAN Moderate Increased risk of bradycardia by the combination of Rivastigmine and Fingolimod. Multiple sclerosis [8A40] [22]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Ozanimod. Multiple sclerosis [8A40] [23]
Neostigmine DM6T2J3 Moderate Additive cholinergic effects by the combination of Rivastigmine and Neostigmine. Myasthenia gravis [8C6Y] [14]
Edrophonium DMCRQHB Moderate Additive cholinergic effects by the combination of Rivastigmine and Edrophonium. Myasthenia gravis [8C6Y] [14]
Ambenonium DMOP0BL Moderate Additive cholinergic effects by the combination of Rivastigmine and Ambenonium. Myasthenia gravis [8C6Y] [14]
Romidepsin DMT5GNL Moderate Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Romidepsin. Mycosis fungoides [2B01] [15]
Nilotinib DM7HXWT Moderate Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Nilotinib. Myeloproliferative neoplasm [2A20] [15]
Dasatinib DMJV2EK Moderate Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Dasatinib. Myeloproliferative neoplasm [2A20] [15]
Phenindamine DMDTC7R Moderate Antagonize the effect of Rivastigmine when combined with Phenindamine. Nasopharyngitis [CA00] [19]
Promethazine DM6I5GR Moderate Antagonize the effect of Rivastigmine when combined with Promethazine. Nausea/vomiting [MD90] [19]
Cyclizine DM9G7BS Moderate Antagonize the effect of Rivastigmine when combined with Cyclizine. Nausea/vomiting [MD90] [19]
Bupropion DM5PCS7 Major Increased risk of lowers seizure threshold by the combination of Rivastigmine and Bupropion. Nicotine use disorder [6C4A] [24]
Levomethadyl Acetate DM06HG5 Moderate Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Levomethadyl Acetate. Opioid use disorder [6C43] [17]
Lofexidine DM1WXA6 Moderate Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Lofexidine. Opioid use disorder [6C43] [15]
Rucaparib DM9PVX8 Moderate Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Rucaparib. Ovarian cancer [2C73] [15]
Flavoxate DMKV4NL Moderate Antagonize the effect of Rivastigmine when combined with Flavoxate. Pain [MG30-MG3Z] [19]
Triclabendazole DMPWGBR Moderate Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Triclabendazole. Parasitic worm infestation [1F90] [15]
Pimavanserin DMR7IVC Moderate Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Pimavanserin. Parkinsonism [8A00] [15]
Orphenadrine DMW542E Moderate Antagonize the effect of Rivastigmine when combined with Orphenadrine. Parkinsonism [8A00] [19]
Methylscopolamine DM5VWOB Moderate Antagonize the effect of Rivastigmine when combined with Methylscopolamine. Peptic ulcer [DA61] [19]
Macimorelin DMQYJIR Moderate Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Macimorelin. Pituitary gland disorder [5A60-5A61] [15]
Lefamulin DME6G97 Moderate Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Lefamulin. Pneumonia [CA40] [15]
Degarelix DM3O8QY Moderate Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Degarelix. Prostate cancer [2C82] [15]
Relugolix DMK7IWL Moderate Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Relugolix. Prostate cancer [2C82] [15]
Levomepromazine DMIKFEL Moderate Antagonize the effect of Rivastigmine when combined with Levomepromazine. Psychotic disorder [6A20-6A25] [19]
Gatifloxacin DMSL679 Moderate Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Gatifloxacin. Respiratory infection [CA07-CA4Z] [15]
Quetiapine DM1N62C Moderate Antagonize the effect of Rivastigmine when combined with Quetiapine. Schizophrenia [6A20] [19]
Aripiprazole DM3NUMH Moderate Antagonize the effect of Rivastigmine when combined with Aripiprazole. Schizophrenia [6A20] [19]
Iloperidone DM6AUFY Moderate Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Iloperidone. Schizophrenia [6A20] [15]
Paliperidone DM7NPJS Moderate Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Paliperidone. Schizophrenia [6A20] [15]
Molindone DMAH70G Moderate Antagonize the effect of Rivastigmine when combined with Molindone. Schizophrenia [6A20] [19]
Thiothixene DMDINC4 Moderate Antagonize the effect of Rivastigmine when combined with Thiothixene. Schizophrenia [6A20] [19]
Asenapine DMSQZE2 Moderate Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Asenapine. Schizophrenia [6A20] [15]
Pimozide DMW83TP Moderate Antagonize the effect of Rivastigmine when combined with Pimozide. Schizophrenia [6A20] [19]
Vandetanib DMRICNP Moderate Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [15]
Triptorelin DMTK4LS Moderate Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [15]
Doxorubicin DMVP5YE Moderate Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [15]
Pitolisant DM8RFNJ Moderate Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Pitolisant. Somnolence [MG42] [15]
Telavancin DM58VQX Moderate Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [15]
Lenvatinib DMB1IU4 Moderate Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Lenvatinib. Thyroid cancer [2D10] [15]
Cabozantinib DMIYDT4 Moderate Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Cabozantinib. Thyroid cancer [2D10] [15]
Chlorpheniramine DM5URA2 Moderate Antagonize the effect of Rivastigmine when combined with Chlorpheniramine. Vasomotor/allergic rhinitis [CA08] [19]
Trimeprazine DMEMV9D Moderate Antagonize the effect of Rivastigmine when combined with Trimeprazine. Vasomotor/allergic rhinitis [CA08] [16]
Acrivastine DMTIGA0 Moderate Antagonize the effect of Rivastigmine when combined with Acrivastine. Vasomotor/allergic rhinitis [CA08] [19]
Propafenone DMPIBJK Moderate Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Propafenone. Ventricular tachyarrhythmia [BC71] [15]
Flecainide DMSQDLE Moderate Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Flecainide. Ventricular tachyarrhythmia [BC71] [15]
⏷ Show the Full List of 109 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
D&C red no. 28 E00491 6097185 Colorant
FD&C blue no. 1 E00263 19700 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Quinoline yellow WS E00309 24671 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Stearic acid E00079 5281 Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Sunset yellow FCF E00255 17730 Colorant
Ammonia E00007 222 Alkalizing agent
Butyl alcohol E00011 263 Flavoring agent; Solvent
Eisenoxyd E00585 56841934 Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Hypromellose E00634 Not Available Coating agent
Magnesium stearate E00208 11177 lubricant
Potassium hydroxide E00233 14797 Alkalizing agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
⏷ Show the Full List of 19 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Rivastigmine 1.5 mg capsule 1.5 mg Oral Capsule Oral
Rivastigmine 6 mg capsule 6 mg Oral Capsule Oral
Rivastigmine 3 mg capsule 3 mg Oral Capsule Oral
Rivastigmine 4.5 mg capsule 4.5 mg Oral Capsule Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6602).
2 BDDCS applied to over 900 drugs
3 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2465).
7 An in vitro study on the interaction of the anti-Alzheimer drug rivastigmine with human erythrocytes. Chem Biol Interact. 2020 Mar 1;319:109019. doi: 10.1016/j.cbi.2020.109019. Epub 2020 Feb 21.
8 Identification of environmental chemicals that activate p53 signaling after in vitro metabolic activation. Arch Toxicol. 2022 Jul;96(7):1975-1987. doi: 10.1007/s00204-022-03291-5. Epub 2022 Apr 18.
9 Potencies and selectivities of inhibitors of acetylcholinesterase and its molecular forms in normal and Alzheimer's disease brain. Acta Biol Hung. 2003;54(2):183-9. doi: 10.1556/ABiol.54.2003.2.7.
10 Inhibition of human carboxylesterases hCE1 and hiCE by cholinesterase inhibitors. Chem Biol Interact. 2013 Mar 25;203(1):226-30.
11 Acteylcholinesterase inhibitor rivastigmine enhances cellular defenses in neuronal and macrophage-like cell lines. Transl Res. 2009 Mar;153(3):132-41. doi: 10.1016/j.trsl.2008.12.003. Epub 2008 Dec 29.
12 Cholinergic drugs potentiate human nicotinic alpha4beta2 acetylcholine receptors by a competitive mechanism. Eur J Pharmacol. 2005 Feb 21;509(2-3):97-108. doi: 10.1016/j.ejphar.2004.12.037.
13 Effect of acetylcholinesterase inhibitors donepezil and rivastigmine on the activity and expression of cyclooxygenases in a model of the inflammatory action of fluoride on macrophages obtained from THP-1 monocytes. Toxicology. 2018 Aug 1;406-407:9-20.
14 Product Information. Aricept (donepezil). Pfizer US Pharmaceuticals, New York, NY.
15 Canadian Pharmacists Association.
16 Carnahan RM, Lund BC, Perry PJ, Chrischilles EA "The concurrent use of anticholinergics and cholinesterase inhibitors: rare event or common practice?" J Am Geriatr Soc 52 (2004): 2082-7. [PMID: 15571547]
17 Cerner Multum, Inc. "Australian Product Information.".
18 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
19 Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC "Explicit criteria for determining inappropriate medication use in nursing home residents." Arch Intern Med 151 (1991): 1825-32. [PMID: 1888249]
20 Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates). Braintree Laboratories, Braintree, MA.
21 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
22 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
23 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
24 Product Information. Wellbutrin XL (buPROPion). GlaxoSmithKline, Philadelphia, PA.